Fig. 8
PDGF-BB promotes MSC migration and protects MSCs against apoptosis via PI3K/Akt signaling. (A-B) Western blot analysis of total and phosphorylated PI3K, Akt, and ERK in MSCs with or without PDGF-BB treatment. PDGF-BB, 50 ng/ml. Values are the mean ± SEM. Significant differences were determined by Student’s t test. N = 6/group. *P < 0.05 vs. vehicle. (C-D) Western blot analysis of CXCR4 in MSCs. LY294002, 10 µM, U0126, 10 µM, 2 h before PDGF-BB treatment. Values are the mean ± SEM. Significant differences were determined by using one-way ANOVA. N = 6/group. *p < 0.01 vs. vehicle; # p < 0.01 vs. PDGF-BB; & p < 0.01 vs. PDGF-BB/LY294002. (E-F). MSC migratory capacities were evaluated by Transwell assay. LY294002, 50 µM. AMD3100, 44 nM. PDGF-BB, 50 ng/ml. Bar, 100 μm. Values are the mean ± SEM. Significant differences were determined by using one-way ANOVA. N = 6/group. *p < 0.01 vs. vehicle; # p < 0.01 vs. PDGF-BB; & p < 0.01 vs. PDGF-BB/AMD3100. (G-H). MSC apoptosis was evaluated by TUNEL assay. Bar, 50 μm. (I-J) Western blot analysis of activated caspase-3 in MSCs. (K-L) Bax and BCL-2 mRNA expression levels were determined by RT‒PCR in MSCs. H2O2, 200 µM, 6 h. LY294002, 30 µM. Values are the mean ± SEM. Significant differences were determined by using one-way ANOVA. N = 6/group. *p < 0.01 vs. vehicle; # p < 0.01 vs. H2O2; & p < 0.01 vs. H2O2/PDGF-BB